HK Stock Market Move | DUIBA (01753) Surges Over 16% Again; AI Short Drama Monthly Sequential Growth Exceeds 1x for Three Consecutive Months; Company Clearly Positions Itself as an AI-Native Content Platform
DUIBA (01753) surged over 16% again, with its share price cumulative gain exceeding 1x within the month. As of press time, it rose 16.78% to HK$0.87, with a turnover of HK$8.8625 million.
DUIBA (01753) rose over 16% again, with cumulative gains of more than 1x within the month. As of press time, it was up 16.78% at HK$0.87, with turnover of HK$8.8625 million.
On the news front, DUIBA recently disclosed a voluntary announcement that its AI short drama business recorded net profit for three consecutive months in July, August, and September. In the third quarter, total new views across all platforms exceeded 45.8 billion, more than 9 times the first-half total of 5 billion. In terms of views, July recorded 6.8 billion, August 12.6 billion, and September 26.4 billion, with month-on-month growth exceeding 100% for three consecutive months. The number of hit dramas with over 100 million views increased from 22 in July to 32 in September, with a peak hit rate of 5.7%, compared with an industry average of only about 0.47%DUIBA is more than 10 times the industry average.
Notably, what DUIBA's third-quarter report reveals is a clearer positioning: an AI-Native content platform. Its core competitiveness is not any single hit drama, but an AI workflow platform and self-developed Agent matrix covering the entire process from "scriptwritingproductiondistributionmonetization." More critically, this capability is being replicated in two directions: overseas, localized dramas have been released on TikTok and YouTube, and a self-developed overseas theater app is planned for launch in the fourth quarter; on WeChat Green Bubble, according to Guosen's October 12 management exchange minutes, the company has already launched operations and is supporting them with WeChat Channels ad spending and heating, with significant growth.
Related Articles

HK Stock Market Move | INNOVENT BIO (01801) rises over 3%; IBI3003 clinical data validate leading position in MM TCE; Phase III registrational study has been advanced in China.

GMTEight List of A-share restricted sales and lifting restrictions | October 21

Guotai Haitong: AI expands boundaries, product experience continues to upgrade; content ecosystem and light production demand drive 3D printing capacity expansion.
HK Stock Market Move | INNOVENT BIO (01801) rises over 3%; IBI3003 clinical data validate leading position in MM TCE; Phase III registrational study has been advanced in China.

GMTEight List of A-share restricted sales and lifting restrictions | October 21

Guotai Haitong: AI expands boundaries, product experience continues to upgrade; content ecosystem and light production demand drive 3D printing capacity expansion.






